Our metabolic-diseased hepatocytes are specifically derived from donors clinically diagnosed with non-alcoholic steatohepatitis (NASH) or Type 2 diabetes, offering a physiologically relevant model for studying liver-related metabolic dysfunction. These cells retain disease-specific phenotypes, including altered lipid accumulation, insulin resistance, and inflammatory responses, making them ideal for evaluating disease mechanisms, therapeutic interventions, and metabolic drug liabilities.
Optimized for advanced DMPK and disease modeling applications, our plateable hepatocytes demonstrate high viability, stable morphology, and reliable attachment. Each lot is thoroughly characterized to ensure consistent disease-relevant functionality, enabling accurate and reproducible data for preclinical research and drug development.